Actin vs Maves (Homera Health)
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Actin
Best for affordable compounded semaglutide with B12 enhancementStarting at $133/mo
Maves (Homera Health)
Best for Performance-oriented buyers (men's health + body optimization framing) seeking aggressive first-month pricing ($99/mo semaglutide intro) with a verifiable LegitScript ID, all-50-state coverage, and brand-plus-parent corporate disclosure (Maves under Homera Health). Strong fit for buyers who prioritize transparency signals (verifiable LegitScript ID + verbatim FDA disclaimer) over named pharmacy partners.Starting at $99/mo
Side-by-Side Comparison
| Feature | Actin | Maves (Homera Health) |
|---|---|---|
| Overall Score | 7.0/10 | ✓7.6/10 |
| Starting Price | $133/mo | ✓$99/mo |
| Editorial Rating | 3.5 ★ /5 | ✓3.8 ★ /5 |
| Features | 2 features | ✓9 features |
| States Available | 0 | ✓50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Actin
Pros
- ✓Semaglutide + B12 combination for added energy support
- ✓Transparent pricing — exact cost shown upfront with no hidden fees
- ✓Competitive starting price from $133
Cons
- ✗Semaglutide only — no tirzepatide or liraglutide
- ✗No visible LegitScript or PCAB accreditation
- ✗State availability not disclosed
- ✗Broader platform (hormones, sexual wellness, hair health)
Maves (Homera Health)
Pros
- ✓LegitScript Certified with publicly verifiable ID (46200381) — strong trust signal beyond just the badge
- ✓Verbatim FDA compounded-medication disclaimer published — meets the WLR transparency standard
- ✓$99/mo first-month intro pricing on semaglutide is among the most aggressive in the WLR directory
- ✓All-50-state coverage explicitly stated (no vague 'most states' language)
- ✓Brand-and-parent disclosure (Maves + Homera Health) gives buyers two trace points for accountability
- ✓Bundled all-inclusive pricing (consult + meds + clinical support + free shipping) — no hidden fees framing matches Elara's transparency
- ✓Performance-driven positioning differentiates from clinical-weight-loss-only competitors and appeals to athletic-buyer segment
Cons
- ✗Specific 503A pharmacy partner NOT named (only 'licensed U.S. pharmacies' generic framing)
- ✗Tirzepatide pricing NOT explicitly stated on the homepage — only listed as an offering
- ✗Named medical director / clinical leadership NOT disclosed
- ✗Refund / cancellation policy NOT publicly detailed
- ✗Governing law / arbitration venue / corporate physical address NOT disclosed
- ✗503B option NOT mentioned (503A pathway implied but not explicitly designated)
- ✗$99/mo is FIRST-MONTH intro — refill / standard pricing not disclosed on homepage; common DTC pattern is step-up at refill
- ✗Men's-health positioning may not align with female-buyer segment despite the platform being available to all patients
Our Verdict
Maves (Homera Health) edges out Actin with a higher overall score of 7.6/10 and is particularly strong for Performance-oriented buyers (men's health + body optimization framing) seeking aggressive first-month pricing ($99/mo semaglutide intro) with a verifiable LegitScript ID, all-50-state coverage, and brand-plus-parent corporate disclosure (Maves under Homera Health). Strong fit for buyers who prioritize transparency signals (verifiable LegitScript ID + verbatim FDA disclaimer) over named pharmacy partners.. Actin remains a solid alternative, especially if you're looking for affordable compounded semaglutide with B12 enhancement.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.